Literature DB >> 36166291

Immobilization-Free Binding and Affinity Characterization of Higher Order Bispecific Antibody Complexes Using Size-Based Microfluidics.

Andreas V Madsen1, Oscar Mejias-Gomez1, Lasse E Pedersen1, Kerstin Skovgaard1, Peter Kristensen2, Steffen Goletz1.   

Abstract

Simultaneous targeting of different antigens by bispecific antibodies (bsAbs) is permitting synergistic binding functionalities with high therapeutic potential, but is also rendering their analysis challenging. We introduce flow-induced dispersion analysis (FIDA) for the in-depth characterization of bsAbs with diverse molecular architectures and valencies under near-native conditions without potentially obstructive surface immobilization. Individual equilibrium dissociation constants are determined in solution, even in higher-order complexes with both antigens involved, hereby allowing the analysis of binding cooperativity and elucidation of a potential interference between the interactions. We further illustrate bispecific binding functionality as incremental increases in complex sizes when the bsAbs are exposed to one or two antigens. The possibility for comprehensive binding analysis with low material consumption and high matrix tolerability irrespective of molecular format and with little optimization renders FIDA a versatile tool for format selection and characterization of complex bi/multispecific protein therapeutics throughout the drug development and biomanufacturing pipeline.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36166291      PMCID: PMC9558742          DOI: 10.1021/acs.analchem.2c02705

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   8.008


  30 in total

Review 1.  Microfluidics and the quantification of biomolecular interactions.

Authors:  Daniel E Otzen; Alexander K Buell; Henrik Jensen
Journal:  Curr Opin Struct Biol       Date:  2021-04-05       Impact factor: 6.809

2.  Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody.

Authors:  Karin Staflin; Christina L Zuch de Zafra; Leah K Schutt; Vanessa Clark; Fiona Zhong; Maria Hristopoulos; Robyn Clark; Ji Li; Mary Mathieu; Xiaocheng Chen; Jennifer Johnston; Justin Low; Ryan Ybarra; Dionysos Slaga; Jihong Yang; Meric Ovacik; Noël O Dybdal; Klara Totpal; Melissa R Junttila; Diego Ellerman; Genee Lee; Mark S Dennis; Rodney Prell; Teemu T Junttila
Journal:  JCI Insight       Date:  2020-04-09

Review 3.  Fusion protein linkers: property, design and functionality.

Authors:  Xiaoying Chen; Jennica L Zaro; Wei-Chiang Shen
Journal:  Adv Drug Deliv Rev       Date:  2012-09-29       Impact factor: 15.470

4.  Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer.

Authors:  Ilse Vaneycken; Nick Devoogdt; Naomi Van Gassen; Cécile Vincke; Catarina Xavier; Ulrich Wernery; Serge Muyldermans; Tony Lahoutte; Vicky Caveliers
Journal:  FASEB J       Date:  2011-04-08       Impact factor: 5.191

5.  FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity.

Authors:  Matthew Kraman; Mustapha Faroudi; Natalie L Allen; Katarzyna Kmiecik; Daniel Gliddon; Claire Seal; Alexander Koers; Mateusz M Wydro; Sarah Batey; Julia Winnewisser; Lesley Young; Mihriban Tuna; Jacqueline Doody; Michelle Morrow; Neil Brewis
Journal:  Clin Cancer Res       Date:  2020-04-16       Impact factor: 12.531

Review 6.  Bispecific T-cell engaging antibodies for cancer therapy.

Authors:  Patrick A Baeuerle; Carsten Reinhardt
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701

7.  Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.

Authors:  Shyhmin Huang; Chunrong Li; Eric A Armstrong; Chimera R Peet; Jarob Saker; Lukas C Amler; Mark X Sliwkowski; Paul M Harari
Journal:  Cancer Res       Date:  2012-11-20       Impact factor: 12.701

Review 8.  The making of bispecific antibodies.

Authors:  Ulrich Brinkmann; Roland E Kontermann
Journal:  MAbs       Date:  2017 Feb/Mar       Impact factor: 5.857

9.  Size-based characterization of adalimumab and TNF-α interactions using flow induced dispersion analysis: assessment of avidity-stabilized multiple bound species.

Authors:  Morten E Pedersen; Ragna M S Haegebaert; Jesper Østergaard; Henrik Jensen
Journal:  Sci Rep       Date:  2021-02-26       Impact factor: 4.379

Review 10.  Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies.

Authors:  Steffen Dickopf; Guy J Georges; Ulrich Brinkmann
Journal:  Comput Struct Biotechnol J       Date:  2020-05-14       Impact factor: 7.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.